Table 3.

Site-specific urogenital tumors and hyperplastic lesions induced by transplacental arsenic exposure together with postnatal diethylstilbestrol or tamoxifen treatment in female CD1 mice; urinary bladder and kidney

Tumor site and typeGroup (n)
Control (33)Arsenic alone (34)DES alone (33)TAM alone (35)Arsenic + DES (33)Arsenic + TAM (35)
Urinary bladder
    Hyperplasia1 (3%)5 (15%)1 (3%)0 (0%)10 (29%) *, 9 (26%) *,
    Papilloma0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)1 (3%)
    Carcinoma0 (0%)0 (0%)0 (0%)0 (0%)3 (9%)0 (0%)
    Total epithelial tumors0 (0%)0 (0%)0 (0%)0 (0%)3 (9%)1 (3%)
    Total proliferative lesions1 (3%)5 (15%)1 (3%)0 (0%)13 (38%) *, , §10 (29%) *,
Kidney
    Hyperplasia0 (0%)1 (3%)0 (0%)0 (0%)0 (0%)1 (3%)
    Carcinoma0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)1 (3%)
  • NOTE: See Table 1 for details. Urinary bladder total proliferative lesions is the incidence of mice bearing at least one uroepithelial preneoplasia, papilloma, or carcinoma. All urinary bladder lesions were of the transitional cell type. The kidney lesions included a renal cell carcinoma and one case of renal cystic tubular hyperplasia both in the arsenic + tamoxifen group. The kidney carcinoma had metastasized to the lung.

  • * Significantly different (P < 0.05) from control.

  • Significantly different (P < 0.05) from diethylstilbestrol alone.

  • Significantly different (P < 0.05) from tamoxifen alone.

  • § Significantly different (P < 0.05) from arsenic alone.